Dyspepsia Market: By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug-Induced Dyspepsia, and Others), By Drug Type (Branded and Generic), By Prescription (Without Prescription Drugs and Prescription Drugs), By Route of Administration (Oral and Injectable), By Distribution Channel (Direct Tender and Retail Sales) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Dyspepsia Market size was valued at USD 9,326.8 million in 2023 and is poised to grow at 4.5% CAGR over the forecast period 2024–2030. Dyspepsia, also known as indigestion, encompasses a range of upper abdominal discomfort or pain, often accompanied by bloating, belching, and nausea. It is a common gastrointestinal disorder that can significantly impact individuals quality of life. According to the World Health Organization (WHO) and the National Institutes of Health (NIH), dyspepsia affects a substantial portion of the global population and it was estimated that around 25-40% of adults experienced dyspeptic symptoms at least occasionally. These symptoms may result from various underlying causes, including gastroesophageal reflux disease (GERD), peptic ulcers, gastritis, and functional dyspepsia.

Functional dyspepsia, a subtype of dyspepsia with no identifiable structural or biochemical abnormalities, has been a subject of particular interest. Studies suggest that it affects approximately 10-20% of the population in Western countries. The burden of dyspepsia is not limited to its prevalence alone it also contributes to a substantial economic impact due to healthcare utilization, including doctor visits, diagnostic tests, and treatments. In the United States, for instance, direct and indirect costs associated with functional dyspepsia have been estimated to be in the billions of dollars annually. Furthermore, dyspepsia is often linked to lifestyle factors such as diet, stress, and smoking. Obesity, too, is a contributing factor, as it can exacerbate symptoms and increase the risk of GERD. While lifestyle modifications and dietary changes are recommended as initial management strategies, pharmacological interventions may also be necessary for some individuals.  

Dyspepsia Market Key Developments:
  • In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
  • In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.

Dyspepsia Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.5%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Dyspepsia Market Dynamics

Dyspepsia, a prevalent gastrointestinal disorder, is poised for dynamic market growth driven by several key factors. Increasing awareness about digestive health, coupled with a rising aging population, is fostering a higher demand for effective dyspepsia management. Lifestyle changes, including unhealthy dietary habits, contribute to the growing incidence of dyspepsia, further propelling market expansion. The pharmaceutical sector's focus on developing innovative and targeted therapies, alongside advancements in diagnostic technologies, creates opportunities for improved treatment options. Additionally, the surge in research activities surrounding novel drug compounds and natural remedies enhances the potential for market evolution. The integration of telemedicine and digital health platforms also facilitates easier access to medical consultation, driving market accessibility. In conclusion, dyspepsia's market dynamics are underpinned by robust growth drivers and a plethora of opportunities, promising a thriving landscape for both the pharmaceutical and healthcare sectors.

Dyspepsia Market Segmentation

By Type

  • Organic Dyspepsia
  • Non-Ulcer Dyspepsia
  • Drug-Induced Dyspepsia

By Drug Type

  •  Branded
  •  Generic

By Prescription

  •  Prescription Drugs
  •  OTC Drugs

By Route of Administration

  •  Oral
  •  Injectable

By Distribution Channel

  •  Direct Tender
  •  Retail Sales

By Geography

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The Dyspepsia market was valued at USD 9,326.8 million in 2022 and is expected to grow at 4.5% CAGR over the forecast period 2023 – 2029.

The Dyspepsia market presents promising prospects driven by growing awareness, innovative diagnostic technologies, and expanding healthcare infrastructure. Personalized treatments, novel therapies, and patient-centric approaches offer avenues for advancement and improved patient outcomes.

Rising focus on non-invasive diagnostic methods, increasing prevalence of lifestyle-related digestive disorders, adoption of precision medicine, and integration of telehealth solutions shape Dyspepsia market trends for enhanced diagnosis and patient care.

Bayer AG, Mankind Pharma, Cadila Pharmaceuticals., Salix Pharmaceuticals, Sanofi, Aosaikand Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Ltd., Lupin. RedHill Biopharma Ltd., Abbott. and Prestige Consumer Healthcare Inc. among others are a few prominent companies operating in the field of Dyspepsia market.

Key Features of the Report

  • The dyspepsia market  report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Dyspepsia Market  Introduction 
2.1.Global Dyspepsia Market   - Taxonomy
2.2.Global Dyspepsia Market   - Definitions
2.2.1.Type 
2.2.2.Drug Type
2.2.3.Prescription
2.2.4.Route of Administration 
2.2.5.Region
3.Global Dyspepsia Market  Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Dyspepsia Market  Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Dyspepsia Market   By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Organic Dyspepsia
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Non-Ulcer Dyspepsia
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Drug-Induced Dyspepsia
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Dyspepsia Market   By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1.  Branded
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2.  Generic
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Dyspepsia Market   By Prescription, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1.  Prescription Drugs
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2.  OTC Drugs
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Dyspepsia Market   By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1.  Oral
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2.  Injectable
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
9.Global Dyspepsia Market   By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Dyspepsia Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Organic Dyspepsia
10.1.2.Non-Ulcer Dyspepsia
10.1.3.Drug-Induced Dyspepsia
10.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1. Branded
10.2.2. Generic
10.3.  Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. Prescription Drugs
10.3.2. OTC Drugs
10.4.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. Oral
10.4.2. Injectable
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Dyspepsia Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Organic Dyspepsia
11.1.2.Non-Ulcer Dyspepsia
11.1.3.Drug-Induced Dyspepsia
11.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1. Branded
11.2.2. Generic
11.3.  Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. Prescription Drugs
11.3.2. OTC Drugs
11.4.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Oral
11.4.2. Injectable
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Dyspepsia Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Organic Dyspepsia
12.1.2.Non-Ulcer Dyspepsia
12.1.3.Drug-Induced Dyspepsia
12.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1. Branded
12.2.2. Generic
12.3.  Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. Prescription Drugs
12.3.2. OTC Drugs
12.4.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. Oral
12.4.2. Injectable
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Dyspepsia Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Organic Dyspepsia
13.1.2.Non-Ulcer Dyspepsia
13.1.3.Drug-Induced Dyspepsia
13.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1. Branded
13.2.2. Generic
13.3.  Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1. Prescription Drugs
13.3.2. OTC Drugs
13.4.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1. Oral
13.4.2. Injectable
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Dyspepsia Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Organic Dyspepsia
14.1.2.Non-Ulcer Dyspepsia
14.1.3.Drug-Induced Dyspepsia
14.2.  Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1. Branded
14.2.2. Generic
14.3.  Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1. Prescription Drugs
14.3.2. OTC Drugs
14.4.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1. Oral
14.4.2. Injectable
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Bayer AG
15.2.2.Mankind Pharma
15.2.3.Cadila Pharmaceuticals
15.2.4.Salix Pharmaceuticals
15.2.5.Sanofi
15.2.6.Aosaikand Pharmaceutical Co., Ltd.
15.2.7.Hanmi Pharm. Co., Ltd.
15.2.8.Lupin
15.2.9.RedHill Biopharma Ltd.
15.2.10.Abbott
15.2.11.Prestige Consumer Healthcare Inc.
16. Research Methodology 
17. Appendix and Abbreviations 
  • Bayer AG
  • Mankind Pharma
  • Cadila Pharmaceuticals
  • Salix Pharmaceuticals
  • Sanofi
  • Aosaikand Pharmaceutical Co., Ltd.
  • Hanmi Pharm. Co., Ltd.
  • Lupin
  • RedHill Biopharma Ltd.
  • Abbott
  • Prestige Consumer Healthcare Inc.

Adjacent Markets